Chardan Capital Has Positive Outlook of OBIO FY2025 Earnings

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - Investment analysts at Chardan Capital upped their FY2025 earnings per share estimates for Orchestra BioMed in a research report issued on Wednesday, April 2nd. Chardan Capital analyst K. Nakae now expects that the company will post earnings of ($1.88) per share for the year, up from their previous estimate of ($1.99). Chardan Capital has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Orchestra BioMed's current full-year earnings is ($1.66) per share.

Other equities research analysts have also issued research reports about the company. Barclays began coverage on Orchestra BioMed in a research report on Thursday, January 2nd. They set an "overweight" rating and a $16.00 price objective on the stock. HC Wainwright reduced their price target on Orchestra BioMed from $14.00 to $12.00 and set a "buy" rating on the stock in a report on Friday, April 4th. BTIG Research started coverage on Orchestra BioMed in a research note on Thursday, March 20th. They issued a "buy" rating and a $12.00 price objective for the company. Finally, B. Riley upgraded shares of Orchestra BioMed to a "strong-buy" rating in a research report on Thursday, April 3rd. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Orchestra BioMed presently has an average rating of "Buy" and an average target price of $15.00.

Orchestra BioMed Stock Up 14.6 %

Shares of NASDAQ OBIO traded up $0.38 during midday trading on Monday, reaching $2.98. 73,724 shares of the company were exchanged, compared to its average volume of 85,885. Orchestra BioMed has a one year low of $2.49 and a one year high of $8.87. The stock has a market cap of $114.17 million, a P/E ratio of -1.85 and a beta of 0.62. The stock's 50-day moving average price is $4.33 and its 200-day moving average price is $5.00.

Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last released its quarterly earnings data on Monday, March 31st. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.43). Orchestra BioMed had a negative net margin of 2,179.33% and a negative return on equity of 107.04%. The business had revenue of $0.25 million during the quarter, compared to analysts' expectations of $0.79 million.

Institutional Trading of Orchestra BioMed

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its stake in shares of Orchestra BioMed by 26.0% in the 4th quarter. SG Americas Securities LLC now owns 12,785 shares of the company's stock valued at $51,000 after purchasing an additional 2,642 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Orchestra BioMed by 11.1% in the fourth quarter. The Manufacturers Life Insurance Company now owns 37,009 shares of the company's stock worth $148,000 after purchasing an additional 3,704 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Orchestra BioMed by 43.6% in the fourth quarter. Wells Fargo & Company MN now owns 13,156 shares of the company's stock valued at $53,000 after buying an additional 3,992 shares during the period. Geode Capital Management LLC lifted its stake in Orchestra BioMed by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 572,441 shares of the company's stock valued at $2,290,000 after buying an additional 5,222 shares during the period. Finally, Northern Trust Corp grew its stake in shares of Orchestra BioMed by 2.5% in the 4th quarter. Northern Trust Corp now owns 236,761 shares of the company's stock valued at $947,000 after buying an additional 5,725 shares during the period. Institutional investors and hedge funds own 53.55% of the company's stock.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.